Acta Pharm Sin B

1. LEUNG EL
   A novel intervention strategy for bladder cancer targeting dual metabolic pathways-Unraveling the pleiotropic mechanisms of quercetin.
   Acta Pharm Sin B. 2026;16:6299-6300.
   

   >> Share

   
   
2. ZHAI Z, Yang F, Feng R, Zhang H, et al
   Quercetin's antitumor effect in bladder cancer: Synergistic regulation of gut microbiota and l-serine metabolic pathway.
   Acta Pharm Sin B. 2026;16:5961-5979.
   

   >> Share

   
   

   
   Am J Case Rep

3. HALALSHEH OM, Hulliel AF, Abualasal A, Aldeqes MI, et al
   Epidermoid Cyst of the Ureter Mimicking Recurrent Urothelial Carcinoma: A Case Report and Brief Literature Review.
   Am J Case Rep. 2026;27:e953801.
   

   >> Share

   
   

   
   Anticancer Agents Med Chem

4. ZHANG X, Yu S, Liu S, Liu M, et al
   Phenanthrene Derivatives from Arundina graminifolia Inhibit the Migration and Proliferation of Human Bladder Cancer Cells.
   Anticancer Agents Med Chem. 2026.
   

   >> Share

   
   

   
   Apoptosis

5. LV Y, Yin Q, Li W, Deng L, et al
   Targeting LAMP2 synergizes with gemcitabine to inhibit bladder cancer progression via modulating STING degradation and regulating macrophage phenotypes.
   Apoptosis. 2026;31:230.
   

   >> Share

   
   
6. LIU J, Zhou Z, Zhang B, Liu R, et al
   GLG1 in cancer-associated fibroblasts promotes bladder cancer growth while limiting tumor apoptosis.
   Apoptosis. 2026;31:232.
   

   >> Share

   
   

   
   Biochem Biophys Res Commun

7. OTA A, Kawai M, Himura R, Maruyama S, et al
   Enhanced NRF1-mediated proteasome bounce-back and nelfinavir-mediated bortezomib sensitization in gemcitabine/cisplatin-resistant bladder cancer cells.
   Biochem Biophys Res Commun. 2026;838:154629.
   

   >> Share

   
   

   
   Biomed Phys Eng Express

8. N P AM, Iyer RS, N PP, B JP, et al
   Task-agnostic explainable contrastive learning model for malignant cell detection in urine cytology.
   Biomed Phys Eng Express. 2026;12.
   

   >> Share

   
   

   
   Biosens Bioelectron

9. LI HZ, Zhu J, Weng GJ, Li JJ, et al
   Application of a magnetic biosensor based on novel cracker-shaped noble metal nanoparticles in dual-modal multidimensional detection of bladder cancer urinary biomarker HAase.
   Biosens Bioelectron. 2026;315:119246.
   

   >> Share

   
   

   
   BMC Urol

10. FAN Q, Fu Z, Zheng X, Wang G, et al
    The "perfect storm" in bladder oncology: a case of diverticular carcinoma with plasmacytoid features and its clinical ramifications.
    BMC Urol. 2026;26:223.
    

    >> Share

    
    
11. LIU C, Zhu Y, Liao Y, Yang X, et al
    A comparative study of robot-assisted laparoscopic radical cystectomy combined with urinary diversion: preoperative indicators and survival outcomes analysis at a single center.
    BMC Urol. 2026;26:225.
    

    >> Share

    
    

    
    Can J Vet Res

12. YAMASAKI H, Hiramatsu H, Nakamichi J, Tei M, et al
    Antitumor effects of CEP32496 on urothelial carcinoma with BRAF mutation (V595E) in dogs.
    Can J Vet Res. 2026;90:121-129.
    

    >> Share

    
    

    
    Cancer Gene Ther

13. WIERENGA KA, Nieland IS, Liu Q, Rakers PRJ, et al
    E2F3 amplification primes bladder cancer cells for premature mitosis.
    Cancer Gene Ther. 2026 Sep 22. doi: 10.1038/s41417-026-01084.
    

    >> Share

    
    

    
    Cancer Invest

14. LI B, Li D, Deng N, Liu P, et al
    Prognostic Value of miR-145 in HER2-Positive Locally Advanced or Metastatic Urothelial Carcinoma Treated with Disitamab Vedotin.
    Cancer Invest. 2026;44:1008-1016.
    

    >> Share

    
    

    
    Curr Oncol

15. CITAKKUL I, Arvas H, Karaoglan M, Koylu B, et al
    Real-World Outcomes of Second-Line Chemotherapy in Metastatic Urothelial Carcinoma.
    Curr Oncol. 2026;33:529.
    

    >> Share

    
    

    
    Drug Resist Updat

16. LIU Y, Wu Y, Li J, Liu T, et al
    Nucleolin shields PTBP1 from autophagic degradation to sustain gemcitabine resistance in bladder cancer.
    Drug Resist Updat. 2026;90:101475.
    

    >> Share

    
    

    
    Ecotoxicol Environ Saf

17. LIU P, Ma M, Wang S, Cao S, et al
    Ca(2)(+)/CaN-mediated NF-kappaB and NFAT activation drives arsenic-induced bladder epithelial pre-malignant behavior.
    Ecotoxicol Environ Saf. 2026;323:120728.
    

    >> Share

    
    

    
    ESMO Open

18. CICCARESE C, Occhipinti D, Troisi P, Shore ND, et al
    Safety profile of BCG with or without immunotherapy in non-muscle-invasive bladder cancer (NMIBC): a systematic review and meta-analysis.
    ESMO Open. 2026;11:108529.
    

    >> Share

    
    
19. COCA MEMBRIBES S, Berney DM, Beltran L, Nally E, et al
    HER1-HER4 expression and co-expression in advanced urothelial carcinoma.
    ESMO Open. 2026;11:108317.
    

    >> Share

    
    

    
    Eur J Med Chem

20. LOPEZ M, Varela M, Ingold M, Lavaggi ML, et al
    Exploring MV14 as a nitric oxide-releasing strategy for bladder cancer: From synthesis to in vivo evaluation.
    Eur J Med Chem. 2026;320:119331.
    

    >> Share

    
    

    
    Eur Urol

21. ELALFY AM
    Re: Valentina Tateo, Giuseppe Basile, Patrizia Giannatempo, et al. Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer. Eur Urol 2026
    Eur Urol. 2026 Sep 25:S0302-2838(26)02372-9. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    

    
    Eur Urol Open Sci

22. LI X, Xing Y
    Re: Nielsen N.K, Hjort P.B, Hansen E.B, et al. Substaging and stratified treatment of T1 bladder cancer - a nationwide register?based study. Eur Urol Open Sci 2026;90:92?100.
    Eur Urol Open Sci. 2026;93:1-2.
    

    >> Share

    
    

    
    Front Immunol

23. WEI X, Pei X, Yu S
    Tertiary lymphoid structures in urothelial carcinoma: bridging spatial architecture with therapeutic vulnerability in the post-BCG era.
    Front Immunol. 2026;17:1853633.
    

    >> Share

    
    
24. LUTJE LS, Gruner C, Karsten CM, Merseburger AS, et al
    Complement tumor-crosstalk: the role of C5a receptors in urothelial carcinomas.
    Front Immunol. 2026;17:1885439.
    

    >> Share

    
    

    
    Front Oncol

25. 
    Correction: Oncobiotics in urinary bladder cancer. A narrative review of living cancer therapeutics.
    Front Oncol. 2026;16:1951323.
    

    >> Share

    
    

    
    Int Urol Nephrol

26. ZAZA MM, ElAzab ME, Ebskharoun SF, Salem TAM, et al
    Evaluation of thulium laser endoscopic en bloc resection versus conventional trans-urethral en bloc resection of primary non-muscle invasive bladder cancer: a randomized controlled trial.
    Int Urol Nephrol. 2026 Sep 22. doi: 10.1007/s11255-026-05390.
    

    >> Share

    
    

    
    J Exp Clin Cancer Res

27. SATASIYA V, Martinelli C, Pascal G, Ducci G, et al
    Functional characterization of FAM120A as a novel effector in the progranulin/EphA2 oncogenic axis in bladder cancer.
    J Exp Clin Cancer Res. 2026;45:205.
    

    >> Share

    
    

    
    J Immunother Cancer

28. ZAKHARIA Y, de Speville BD, Morales-Barrera R, Moreno I, et al
    Phase 1 study of KHK2455, a long-acting, potent and selective IDO1 inhibitor, in combination with avelumab in patients with locally advanced or metastatic urothelial carcinoma.
    J Immunother Cancer. 2026;14:e015178.
    

    >> Share

    
    

    
    J Infect Public Health

29. LIU PT, Hsu WL, Chen TI, Chiang CJ, et al
    Association between cervical human papillomavirus infection and bladder cancer risk: A community-based cohort study.
    J Infect Public Health. 2026;19:103377.
    

    >> Share

    
    

    
    J Magn Reson Imaging

30. UENO Y, Sofue K, Murakami T
    Editorial for "Associations of Anatomical Location and Reader Experience With the Diagnostic Performance of Multiparametric MRI-Derived VI-RADS for Muscle Invasive Bladder Cancer: A Multicenter Multireader Study".
    J Magn Reson Imaging. 2026 Sep 22. doi: 10.1002/jmri.70561.
    

    >> Share

    
    
31. WANG X, Sun F, Hu J, Huang X, et al
    Associations of Anatomical Location and Reader Experience With the Diagnostic Performance of Multiparametric MRI-Derived VI-RADS for Muscle Invasive Bladder Cancer: A Multicenter Multireader Study.
    J Magn Reson Imaging. 2026 Sep 22. doi: 10.1002/jmri.70557.
    

    >> Share

    
    

    
    J Robot Surg

32. KIM M, Lee J, Shin YS, Nguyen TT, et al
    Oncological and perioperative outcomes of robot-assisted radical cystectomy: a real-world cohort study emulating a target trial.
    J Robot Surg. 2026;20:1023.
    

    >> Share

    
    

    
    J Urol

33. NUSBAUM DJ, Gilbert SM, Li R
    Simpler risk stratification and new options for recurrent low-grade disease: 2026 update to the AUA/SUO non-muscle invasive bladder cancer guideline.
    J Urol. 2026 Sep 24:101097JU0000000000005323. doi: 10.1097/JU.0000000000005323.
    

    >> Share

    
    

    
    J Vis Exp

34. HE Y, Kong H, Zhang C, Li Y, et al
    Bladder Large Cell Neuroendocrine Carcinoma(LCNEC): A Case Report of Exfoliated Cytology and Pathological Characteristics.
    J Vis Exp. 2026;.
    

    >> Share

    
    

    
    JCO Oncol Pract

35. DAVIS ID
    How Do I Treat the Very Elderly With Advanced Bladder Cancer as We Have so Many New Agents?
    JCO Oncol Pract. 2026 Sep 22:OP2601009. doi: 10.1200/OP-26-01009.
    

    >> Share

    
    

    
    Oncol Res

36. BAI Z, Song X, Sun J, Xiao W, et al
    Bladder Cancer Biomarkers: Recent Advances in Early Detection, Treatment Prediction, and Prognosis.
    Oncol Res. 2026;34:19.
    

    >> Share

    
    
37. CHEN S, Gan X, Lv P, Meng Q, et al
    Comparison of Neoadjuvant Chemotherapy, Chemoimmunotherapy, and Upfront Radical Cystectomy in High-Risk Bladder Cancer: A Single-Center Retrospective Study.
    Oncol Res. 2026;34:16.
    

    >> Share

    
    
38. SPIRITO L, Quintavalle C, Coppola P, Esposito M, et al
    Nanorobots and Exosomes: Driving the New Frontier for Bladder Tumors through Non-Coding RNAs.
    Oncol Res. 2026;34:8.
    

    >> Share

    
    

    
    PLoS One

39. WU Y, Li G, Jiang L, Zhang C, et al
    A recurrent cancer-associated fibroblast/TGF-beta/endothelial barrier direction is associated with immune exclusion and checkpoint resistance in bladder cancer: a public multi-cohort transcriptomic study.
    PLoS One. 2026;21:e0358043.
    

    >> Share

    
    
40. XU S, Xie H, Yang Z, Ma Z, et al
    PAK4-targeting PROTAC inhibits bladder cancer cell proliferation.
    PLoS One. 2026;21:e0358561.
    

    >> Share

    
    

    
    Res Vet Sci

41. SUGIUCHI M, Tajima K, Ando R, Yamashita Y, et al
    Corneal stromal metastasis of urothelial carcinoma in a dog.
    Res Vet Sci. 2026;211:106374.
    

    >> Share

    
    

    
    Rev Med Inst Mex Seguro Soc

42. PALE-GONZALEZ GA, Diaz-Fuentes H
    [Nested variant of urothelial carcinoma complicated with pulmonary lymphangitis carcinomatosis. Case report].
    Rev Med Inst Mex Seguro Soc. 2026;64:e7099.
    

    >> Share

    
    

    
    Urol J

43. LI Y, Liu Y
    Ileum vs Colon for Neobladder Reconstruction After Radical Cystectomy: A Systematic Review and Meta-Analysis.
    Urol J. 2026;23:122-132.
    

    >> Share

    
    

    
    World J Nucl Med

44. SIN C, Esen Akkas B, Vural Topuz O, Omak O, et al
    Diuretic-Enhanced Dual-Phase F-18 FDG PET/CT: A New Window Into Muscle-Invasive Bladder Cancer.
    World J Nucl Med. 2026;25:242-249.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share